PYXS · Pyxis Oncology, Inc. · Executive Compensation
$2.24
+0.10 (+4.67%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements were issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$238.55M
Shares
83.41M
Volume · Oct 5
1.52M
Avg daily vol (3M)
1.27M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | Former President, Chief Executive Officer and Chief Medical Officer | $1,671,545 |
| Pamela Connealy | Former Chief Financial Officer and Chief Operating Officer | $1,425,237 |
| Jitendra Wadhane | Principal Financial and Accounting Officer | $766,752 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | President, Chief Executive Officer and Chief Medical Officer | $7,072,943 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $2,571,039 |
| Ken Kobayashi | Former Chief Medical Officer | $650,350 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | President, Chief Executive Officer and Chief Medical Officer | $4,442,501 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $1,821,359 |
| Jay Feingold | M.D., Ph.D. Former Chief Medical Officer | $1,053,444 |
| Ken Kobayashi | Former Chief Medical Officer | $880,013 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | President and Chief Executive Officer | $5,027,073 |
| Jay Feingold | M.D., Ph.D. Former Chief Medical Officer | $2,393,445 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $2,026,612 |
| Ken Kobayashi | Chief Medical Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | M.D., President and Chief Executive Officer | $17,268,336 |
| Jay Feingold | M.D., Ph.D., Chief Medical Officer | $7,710,098 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | $2,735,364 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lara Sullivan | M.D., Chief Executive Officer | $555,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John Flavin | Lead Independent Director | Appointed | 2026-09-08 |
| Santhosh Palani | member of the Company's Board | Resigned | 2026-09-08 |
| Thomas Civik | Chairman of the Board | Appointed | 2026-09-08 |
| Thomas Civik | Chief Executive Officer | Appointed | 2026-09-08 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | Retired | 2025-07-03 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | Retired | 2025-07-03 |
| Ken Kobayashi, M.D., F.A.C.P | Chief Medical Officer | Resigned | 2025-03-18 |
| Michael A. Metzger | Board of Directors | Appointed | 2024-06-10 |
| Santhosh Palani, Ph.D., CFA | Board of Directors | Appointed | 2024-03-13 |
| Ken Kobayashi, M.D., F.A.C.P | Chief Medical Officer | Appointed | 2023-11-28 |
| Jakob Dupont, M.D. | Class III director | Appointed | 2023-08-23 |
| Pamela Connealy | Chief Financial Officer and Chief Operating Officer | Appointed | 2023-03-22 |
| Rachel Humphrey, M.D. | Board of Directors | Appointed | 2022-08-15 |
| Jitendra Wadhane | Chief Accounting Officer and to serve as Principal Accounting Officer | Appointed | 2022-08-09 |